Alto Neuroscience Class Action Lawsuit: Important Deadline Approaching for Investors

Purchasers of common stock of Alto Neuroscience, Inc. who bought shares pursuant to the company's initial public offering on February 2, 2024, or securities between February 2, 2024, and October 22, 2024, may be entitled to compensation without paying out-of-pocket fees or costs through a contingency fee arrangement. A class action lawsuit has been filed against Alto, and a lead plaintiff must be appointed by September 19, 2025, to move the litigation forward.

Key Takeaways:

• The lawsuit alleges that Alto made false and misleading statements regarding its business, operations, and prospects, specifically regarding the effectiveness of its ALTO-100 treatment for major depressive disorder.
• Investors who purchased Alto securities during the Class Period may be entitled to compensation through a contingency fee arrangement.
• A lead plaintiff must be appointed by September 19, 2025, to direct the litigation and represent other class members.
• The Rosen Law Firm, a global investor rights law firm, is leading the class action lawsuit and has a track record of success in securities class actions and shareholder derivative litigation.
• The firm has secured hundreds of millions of dollars for investors and has been ranked consistently as a top securities class action firm.

Statistics:

• The Alto class action lawsuit covers shares purchased between February 2, 2024, and October 22, 2024, both dates inclusive.
• The lead plaintiff deadline is September 19, 2025.
• The Rosen Law Firm has secured over $438 million for investors in 2019 alone.
• The firm has been ranked in the top 4 for securities class action settlements every year since 2013.

Sources:

• Newsfile Corp. - "Alto Neuroscience Class Action Lawsuit (ANRO) - Lead Plaintiff Deadline Is Approaching" (August 18, 2025)
• The Rosen Law Firm, P.A. - "Alto Neuroscience Class Action Lawsuit" (August 18, 2025)
• Law360 - "Laurence Rosen Named Titan of Plaintiffs' Bar" (2020)